Tempest Therapeutics Inc

Research Tempest Therapeutics Inc (TPST) on Bullrun: market cap USD 16.29M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerTPST
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 16.29M
• Financial periodFY2025
• Net income-USD 26.26M
• Free cash flow-USD 26.82M

Valuation Snapshot

latest market cap is USD 16.29M.

About Tempest Therapeutics Inc

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers.

Frequently asked questions

What is Tempest Therapeutics Inc's market cap?

Tempest Therapeutics Inc's market capitalization is USD 16.29M.

What does Tempest Therapeutics Inc do?

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer.